Rapamycin vs Metformin for Longevity: What the Evidence Actually Shows (2026)
If you’ve read anything about longevity science in the past five years, you’ve seen rapamycin and metformin compared endlessly. I’ve literally made investments in companies developing both compounds for aging. But here’s what bothers me: most comparisons are oversimplified. People say “rapamycin is stronger” or “metformin has more data,” and then you end up with someone taking rapamycin without understanding mTOR inhibition, or taking metformin expecting results it doesn’t deliver. Both work. They work completely differently. And one is definitely a better fit for your situation depending on what you’re actually trying to achieve.
Let me walk you through the mechanisms, the human trial data we actually have, the honest limitations, and who should be taking what.
Quick Comparison Table
| Factor | Rapamycin | Metformin |
|---|---|---|
| Mechanism | mTOR inhibition | AMPK activation, mitochondrial stress |
| Approval status | FDA-approved (immunosuppressant) | FDA-approved (diabetes) |
| Off-label longevity use | Common in biohacking; limited human data | Widespread; more human data |
| Lifespan extension (mice) | ~18% extension (ITP) | ~11% extension (ITP) |
| Human longevity trials | PEARL trial (ongoing); no results yet | TAME trial (active, 3000+ subjects) |
| Dosing (standard) | 5–10 mg weekly (pulsatile) | 500–2000 mg daily |
| Half-life | ~57 hours (long, allows weekly dosing) | ~6.2 hours (requires BID dosing) |
| Side effect severity | Moderate (immunosuppression, lipid effects) | Mild (GI distress, B12 issues) |
| Best for ages | 50–75 (aging adults with solid health) | 40–80 (broader age range) |
| Metabolic effect | Reduces mTOR signaling; improves autophagy | Increases AMPK; improves glucose control |
| Cost per month | $50–$200 (varies by dosing) | $10–$40 |
| Drug interactions | Significant (affects many pathways) | Mild to moderate |
| Monitoring required | Blood work (lipids, glucose, immunology) | Minimal (B12 levels annually) |
| Realistic lifespan gain | Unknown in humans; 1–3 years possible | Unknown in humans; <1 year likely if proven |
| Best for | Systemic aging, metabolic decline | Metabolic syndrome, glucose control |
| Worst for | Immunocompromised, active infections | Renal disease, pregnancy |
The article continues with comprehensive analysis…